s:** - Test whether HCN1 knockout specifically in EC layer II accelerates or protects against AD pathology - Measure whether pharmacological HCN1 enha

🧫 Experiment Protocol FalsificationAlzheimer's DiseaseHCN1cell_lineproposed

# s:** - Test whether HCN1 knockout specifically in EC layer II accelerates or protects against AD pathology - Measure whether pharmacological HCN1 enha ## Background and Rationale This experiment investigates the specific role of HCN1 channels in entorhinal cortex layer II neurons and their contribution to Alzheimer's disease pathology progression. HCN1 (Hyperpolarization-activated Cyclic Nucleotide-gated channel 1) channels are critical for neuronal excitability and rhythmic activity, particularly in the entorhinal cortex layer II stellate cells that serve as a major input to the hippocampus. These neurons are among the earliest affected in Alzheimer's disease, and HCN1 dysfunction may contribute to network hyperexcitability and tau pathology spreading. The experimental approach utilizes cell culture models to test whether HCN1 knockout specifically in layer II entorhinal cortex neurons accelerates or protects against AD pathology development. Primary neuronal cultures derived from entorhinal cortex will be genetically modified using CRISPR-Cas9 to knockout HCN1 expression, followed by treatment with amyloid-beta oligomers and tau seeds to model AD pathology. Parallel experiments will test pharmacological HCN1 enhancement using selective agonists to determine whether boosting HCN1 function provides neuroprotection. The study will assess neuronal survival, tau phosphorylation patterns, synaptic function, and network excitability using patch-clamp electrophysiology and calcium imaging. This research could reveal whether HCN1 channels represent viable therapeutic targets for early-stage Alzheimer's intervention by modulating entorhinal cortex hyperexcitability. This experiment directly tests predictions arising from the following hypotheses: - **HCN1-Mediated Resonance Frequency Stabilization Therapy** - **Gamma entrainment therapy to restore hippocampal-cortical synchrony** - **Sleep Spindle-Synaptic Plasticity Enhancement** - **Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation** - **Prefrontal sensory gating circuit restoration via PV interneuron enhancement** ## Experimental Protocol **Phase 1: Cell Culture Preparation (Days 1-7)** • Establish iPSC-derived entorhinal cortex layer II neurons from control and AD patient lines (n=6 each) • Generate HCN1 knockout cell lines using CRISPR/Cas9 with gRNAs targeting exons 2-3 of HCN1 • Validate knockout efficiency by qRT-PCR and Western blot (>95% reduction required) • Maintain cultures in Neurobasal-A medium with B27 supplement at 37°C, 5% CO2 **Phase 2: Pathology Induction and Treatment (Days 8-35)** • Treat cells with Aβ42 oligomers (1-5 μM) and tau K18 fibrils (100-500 nM) to induce AD-like pathology • Apply pharmacological treatments: ZD7288 (HCN1 blocker, 10-100 μM) and ivabradine (HCN1 enhancer, 1-10 μM) • Establish experimental groups: Control, AD pathology, AD+HCN1 KO, AD+ZD7288, AD+ivabradine • Monitor cell viability daily using MTT assay and live/dead staining **Phase 3: Molecular Analysis (Days 21, 28, 35)** • Collect samples for Western blot analysis of phospho-tau (AT8, PHF-1), total tau, Aβ levels • Perform immunofluorescence for HCN1, MAP2, cleaved caspase-3, and pathological markers • Measure HCN1 current density using whole-cell patch-clamp electrophysiology • Quantify mitochondrial function via seahorse metabolic analysis and TMRM staining **Phase 4: Functional Assessment (Days 30-35)** • Record spontaneous neuronal activity using multi-electrode arrays (60-electrode setup) • Measure synaptic protein levels (PSD95, synaptophysin, VGAT, VGLUT1) by Western blot • Assess neurite outgrowth and complexity using high-content imaging analysis • Perform TUNEL assay and annexin V staining for apoptosis quantification ## Expected Outcomes 1. **HCN1 knockout in EC layer II neurons will accelerate AD pathology**, showing 30-50% increased tau phosphorylation and 25-40% higher cell death compared to wild-type controls after Aβ/tau treatment 2. **Pharmacological HCN1 enhancement with ivabradine will provide neuroprotection**, demonstrating 20-35% reduction in neuronal death and 15-30% decrease in pathological tau markers in AD model cells 3. **HCN1 manipulation will be downstream of initial Aβ/tau pathology**, with changes in HCN1 expression/function occurring 7-14 days after pathology induction but not affecting initial Aβ accumulation levels 4. **Electrophysiological dysfunction will precede cell death**, showing 40-60% reduction in spontaneous firing rates and network connectivity 5-10 days before significant cell loss in HCN1 knockout conditions 5. **Mitochondrial dysfunction will correlate with HCN1 loss**, demonstrating 25-45% decreased ATP production and 30-50% increased ROS levels in HCN1 knockout neurons under AD conditions 6. **Synaptic protein loss will be exacerbated by HCN1 knockout**, showing 35-55% greater reduction in presynaptic and postsynaptic markers compared to controls with intact HCN1 function ## Success Criteria • **Statistical significance threshold**: p<0.05 with Bonferroni correction for multiple comparisons, minimum effect size Cohen's d>0.5 for primary endpoints • **Sample size adequacy**: Minimum n=6 biological replicates per condition with ≥3 technical replicates, power analysis confirming >80% power to detect 25% difference between groups • **HCN1 manipulation validation**: >90% knockdown efficiency confirmed by qRT-PCR and Western blot, >50% change in HCN current density measured by electrophysiology • **Pathology induction verification**: Significant increase (p<0.01) in phospho-tau levels and Aβ accumulation in treated vs control conditions, confirmed by at least two independent methods • **Dose-response relationship**: Pharmacological effects must show clear dose-dependency across 3+ concentrations with IC50/EC50 values within expected ranges (1-100 μM for modulators) • **Temporal consistency**: Primary outcomes must be reproducible across at least 2 time points (day 21 and 35) and validated in minimum 2 independent experimental runs

Source: debate_extraction

🧫 Experiment Extras

🔴 Alzheimer's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found